CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion. Wang S, Iyer R, Han X, Wei J, et al. J Clin Invest 2023;133:e167728.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wang S, Iyer R, Han X, Wei J, et al. CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion. J Clin Invest 2023;133:e167728.
PMID: 38038129